The Human Phenotype Ontology (HPO) provides the following list of features that have been reported in people with this condition. Much of the information in the HPO comes from Orphanet, a European rare disease database. If available, the list includes a rough estimate of how common a feature is (its frequency). Frequencies are based on a specific study and may not be representative of all studies. You can use the MedlinePlus Medical Dictionary for definitions of the terms below.
|Signs and Symptoms||Approximate number of patients (when available)|
|Abnormality of coagulation||90%|
|Thickened nuchal skin fold||90%|
|Abnormality of the endocardium||7.5%|
|Abnormality of the mitral valve||7.5%|
|Abnormality of the palate||7.5%|
|Abnormality of the thorax||7.5%|
|Abnormality of thrombocytes||7.5%|
|Coronary artery disease||7.5%|
|Sudden cardiac death||7.5%|
|Telangiectasia of the skin||7.5%|
|Abnormality of the mouth||-|
|Angioid streaks of the retina||-|
|Autosomal recessive inheritance||-|
|Congestive heart failure||-|
|Mitral valve prolapse||-|
|Reduced visual acuity||-|
The 11th Annual North American Genetic Analysis of ABC Transporters Workshop
Wednesday, September 24, 2014 -
Thursday, September 25, 2014
Location: NCI-Frederick, Frederick, MD
Description: This workshop features presentations from graduate students, post-docs., and senior investigators studying the role of ATP Cassette Binding Proteins in human disease. Phylogenetic studies, model systems, and bioinformatic techniques that shed light in this rapidly developing research area are presented. Because student presentations predominate, unpublished results often are first disclosed at these workshops.
Contact: Dr. Michael Dean,(301) 846-5931,firstname.lastname@example.org
Co-funding Institute(s): National Cancer Institute, Office of Rare Diseases Research
Pseudoxanthoma Elasticum Research 2010 Conference
Monday, November 29, 2010 -
Tuesday, November 30, 2010
Location: North Bethesda Marriott , Bethesda, MD
Description: The specific aims of this conference were to review the current status of basic and translational research on pseudoxanthoma elasticum (PXE), determine the most relevant biomarkers and clinical endpoints in preparation for clinical trials, and evaluate a number of hypothetical therapeutic interventions including vitamin K therapy and anti-angiogenesis therapies. Additionally, meeting participants reviewed the understanding of the clinical manifestations of PXE in order to come to consensus on diagnostic criteria. The results of the meeting will be used to plan for future research and translational applications.
Contact: Hung Tseng, Ph.D., (301) 496-0810, email@example.com
Co-funding Institute(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases, Office of Rare Diseases Research
Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know. Submit a new question
Is it recommended to take an antibiotic or other medication before a dental procedure with pseudoxanthoma elasticum? See answer
My mother was diagnosed with pseudoxanthoma elasticum, but no one in the previous three generations of my father's family have been diagnosed with this condition. Now I have a baby who seems to have lumps which look like pseudoxanthoma elasticum on his neck, but no one in the previous three generations of my husband's family have been diagnosed with this condition. My questions are:
1. How can I know whether or not my husband or I are unaffected carriers? What type of blood test do I need to have?
2. Several websites say that pseudoxanthoma elasticum is untreatable. Is that true? Can the progression of this condition be slowed down or managed?
3. My baby was only 3-4 months old when I saw the yellow lumps on his neck, but I read that the average age for the onset of symptoms is in the teens. Is it possible for a baby to show symptoms? See answer